Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03434366
Recruitment Status : Recruiting
First Posted : February 15, 2018
Last Update Posted : July 11, 2018
Sponsor:
Information provided by (Responsible Party):
Ying Jun She, MD, Guangzhou Women and Children's Medical Center

Brief Summary:

Autism spectrum disorder (ASD) is a life-long neurodevelopmental disorder characterized by qualitative abnormalities in reciprocal social interactions and patterns of communication, and by a restricted, stereotyped, repetitive repertoire of interests and activities. The use of medications in adolescents and young adults with ASD is extremely common. However, few data address the effectiveness and harms of medications specifically in this population.

The purpose of the study is to determine the efficacy and safety of intranasal ketamine with dexmedetomidine in children with ASD.


Condition or disease Intervention/treatment Phase
Autism Spectrum Disorder Drug: ketamine and dexmedetomidine Drug: ketamine Drug: Saline Phase 2

Detailed Description:
The use of medications in adolescents and young adults with ASD is extremely common. few data address the effectiveness and harms of medications specifically in this population. A previous study reported the first case study demonstrating clinical improvement in mood and eye fixation scores from intranasal ketamine treatment in a "complicated" subject with autism spectrum disorderHowever,The purpose of the study is to determine the efficacy and safety of intranasal ketamine with dexmedetomidine in children with ASD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder
Actual Study Start Date : January 20, 2018
Estimated Primary Completion Date : May 30, 2019
Estimated Study Completion Date : June 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ketamine and dexmedetomidine group
intranasal ketamine and dexmedetomidine was treated in the children
Drug: ketamine and dexmedetomidine
intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
Other Name: intranasal ketamine and dexmedetomidine

Experimental: ketamine group
intranasal ketamine was treated in the children
Drug: ketamine
intranasal ketamine for treatment for autism spectrum disorder
Other Name: intranasal ketamine

Placebo Comparator: control group
intranasal insaline was used in the children
Drug: Saline
intranasal saline for treatment for autism spectrum disorder
Other Name: intranasal saline




Primary Outcome Measures :
  1. Autism Diagnostic Interview Revised (ADI-R) [ Time Frame: change from baseline at 2, 5 and 12 weeks ]
    The Autism Diagnostic Interview Revised is an investigator-based semi-structured diagnostic interview, The ADI-R provides empirically derived diagnostic algorithms for three subdomains of qualitative impairments. The social interaction domain includes questions about emotional sharing, offering and seeking comfort, social smiling, and social responding comprising four subscores. The second domain (communication) assesses stereotyped expressions, pronoun reversal, and the social usage of language (B1-B4). In the third domain repetitive and stereotyped behavior as hand- and finger mannerisms, unusual sensory interest or activities are investigated by four subscales. Most items are scored from zero to three, relying on the interviewer to make judgements on child's behaviour based on the recall of information from parents/carers. . A total score is then calculated for each of the three subdomains. The ADI-R has an algorithm for autism based on scores in these three areas and on onset.

  2. Autism Diagnostic Observation Schedule (ADOS) [ Time Frame: change from baseline at 2, 5 and 12 weeks ]
    The Autism Diagnostic Observation Schedule (ADOS) is a semi-structured assessment of communication, social interaction and play or imaginative use of materials for individuals suspected of having autism or other ASD. It consists of four modules, each of which is appropriate for children, adolescents and adults of differing developmental and language levels, ranging from no expressive or receptive language to verbally fluent adults. The examiner selects the module that is most appropriate for a particular child, adolescent on the basis of his/her expressive language level and chronological age. Selected algorithm items relating to social interaction and communication are then entered into an algorithm. The scores must meet the separate cut-offs for both the communication and social domains and the cut-off for the summation of the two. Repetitive behaviours are recorded and coded as part of the clinical observations but do not contribute to the ADOS summary algorithm.


Secondary Outcome Measures :
  1. autism behavior checklist (ABC) [ Time Frame: change from baseline at 2, 5 and 12 weeks ]
    ABC is a scale used for nonadaptive behaviors created to screen and indicate the probability of a diagnosis of autism. The questionnaire approaches 57 atypical behaviors related to five areas: sensorial, relational, use of body and objects, and social skills. Scales> 67 was diagnosised ASD, compare the change in scales in different time point(from baseline to endpoint)

  2. magnetic resonance spectroscopy(MRS) [ Time Frame: change from baseline at 5 and 12 weeks ]
    compare the metabolite concentrations and ratios in brain from Baseline to Endpoint (NAA,Glu,Gln,Cho,Cr,mI)

  3. Childhood Autism Rating Scale (CARS) [ Time Frame: change from baseline at 2, 5 and 12 weeks ]
    CARS assesses the child on a scale from 1 to 4 in each of 15 dimensions or symptoms (including the ability to relate to people, emotional response, imitation, body use, object use, listening response, fear or nervousness, verbal communication, nonverbal communication, activity level, level and reliability of intellectual response, adaptation to changes, visual response, taste, smell and touch responses and general impressions). A total score of at least 30 strongly suggests the presence of autism. Children who score between 30 and 36 have mild-to-moderate autism while those with scores between 37 and 60 have severe autism. Change in CARS from Baseline to Endpoint.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. meet autism diagnostic criteria based on DSM-5/ADI-R/ADOS
  2. children aged 2 years through 15 years of age
  3. parents/guardians can cooperate with the study and sign informed consent
  4. ASA score I or II

Exclusion Criteria:

  1. with epilepsy or other genetic diseases
  2. changes in drugs or in any intervention during the study
  3. Presence of cardiac disease including coronary artery disease, congestive heart failure, or uncontrolled hypertension per medical history
  4. Airway instability, tracheal surgery, or tracheal stenosis per medical history.
  5. History of drug or alcohol abuse
  6. Central nervous system masses or hydrocephalus per medical history

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03434366


Contacts
Layout table for location contacts
Contact: YJ She, Dr. 862038076243 yjsheh@yeah.net

Locations
Layout table for location information
China, Guangdong
Guangzhou Women and Children Medical Center Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Ying-Jun She, Doctor    862038076243    yjsheh@yeah.net   
Sponsors and Collaborators
Guangzhou Women and Children's Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Qing Zhao, Doctor Guangzhou Women and Children's Medical Center

Layout table for additonal information
Responsible Party: Ying Jun She, MD, Department of Anesthesiology, Guangzhou Women and Children's Medical Center
ClinicalTrials.gov Identifier: NCT03434366     History of Changes
Other Study ID Numbers: intranasal ketamine
First Posted: February 15, 2018    Key Record Dates
Last Update Posted: July 11, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ying Jun She, MD, Guangzhou Women and Children's Medical Center:
Autism Spectrum Disorder
ketamine
dexmedetomidine

Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Pathologic Processes
Neurodevelopmental Disorders
Mental Disorders
Dexmedetomidine
Ketamine
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents